Member Info for Appiamma

Quite agree Snaffle - StoneChecker FDA is often seen as the only thing that matters. Much more going on in this company now and much of it is overlooked. Even the fact that StoneChecker has CE seems to be ignored. IB Neuro and Clinic already have FDA. I encourage people to read the operational information in the last annual report: https://www.iq-ai.ltd/wpib/wp-content/uploads/2019/04/IQ-AI-Annual-Report-2018-12-31.pdf

A few highlights:

Existing Products: '...During 2018, the Company sold or trialed software at many of the United States’ most well-regarded hospitals and specialist clinics. IB Neuro remains the only ‘biopsy confirmed’ neuro perfusion software available on the market.'

Fee Per Click and IB Server: '...The IB server is currently being tested at a major US neurological institution with one other beta site currently being deployed.'

AI: '...IB has recently expanded its development team with software engineers experienced in artificial intelligence (“AI”). The Company intends to strategically incorporate AI to further enhance and automate its fractional tumour burden (“FTB”) mapping for brain tumour treatment monitoring'

PC-based version of IB Plugins to expand compatibility: '...In 2018, IB completed the integration of its products into the PC-based DICOM platform ClearCanvas (Synaptive Medical, Toronto, CA). Once validation is complete, the release of IB Software within the ClearCanvas environment will give institutions a PC-based option to access and leverage IB’s quantitative biomarkers.

Remember this is just the beginning and the CoreTechs Labs agreement can only accelerate sales. As the company states:

'The Company’s products are now sold in the USA, UK, The Netherlands, Switzerland, Germany, Greece and South Korea. Our objectives for 2019 are to expand sales and continue to develop new products which utilise areas of our expertise where we believe we have scientific and technological leadership. As a result of product development and new users, sales have continued to accelerate in 2019. We expect sales for the full year 2019 to more than double those for 2018. The future looks to be an exciting place for IQ-AI.'

Did you make a huge mistake? Buying a stock with zero research what do you think? Fortunately for you your rashness has left you holding a stock with huge potential, but do yourself a favour, research your purchase and you may even consider buying more.

Again very resilient today in the face of heavy selling. Agreed that it looks like the placing stock being sold and it may take some time. Still view it as a massive positive that they raised at 3 times the SP from a few weeks ago, they have ensured they are cashed up for the post FDA sales push and once the stock dries up again away it will go.GLA

What pressure from the CLNs would that be? They are owned by the chairman and he has chosen to extend the redemption date on his CLNs before. Maybe TB thinks of them as a a loan to the company. He has his 6% and he can choose to let the company buy them back at the right time. He has said publicly that he intends to fully support the company financially and so far he's been good to his word. Oh and btw this is not an AIM company

Forgive me - it's early - just realised that of course should read Thursday afternoon - Friday morning.

Almost certainly a sell looking at the bid at the time and how the SP dropped afterwards, much as the 2 x 300k marked as sells are probably buys for the same reason. Never go just by what LSE marks them down as. However as I said before, despite some heavy selling yesterday afternoon and this morning, it has held up well and will hopefully consolidate until we get more news. And if the large sells have dried up for the moment those wishing to get on board will find stock hard to come by.

SP has proved to be pretty resilient considering the significant selling today. Stock drying up a bit so hopefully the profit takers are done for a while.

The 8:16 and 8:39 both look like sells from this morning - hence the drop. Coming back slowly though

I think what frustrates most folk is that whereas most E&Ps struggle to actually find hydrocarbons - we actually know the stuff is there we just can't seem to get it out the ground. Lets hope this well marks a turning point for this company - even just a small win - proof of competency - would be very significant for the SP imo. GLA

This got a bit overheated today for a while and many took some profit. But still closed with a decent rise and at a more sensible SP possibly, the 4p level it was at 12 months ago. Why did it drop so low in the first place? Who knows, probably the FDA delays or worries about funding, but mostly because people just got bored of waiting - certainly nothing major. In those 12 months there has been real progress and the CorTechs Labs news last week brought that into focus. The SP had a clear path to re-rate to here, but beyond this point may be tougher I think. MCAP is still low imo but it's still valued on potential and investors will need to see contract wins and revenue increases in the coming months.

Ezhik I apologise - I was feeling a little facetious at the time - in fact I've been feeling that way for some months. In my defense I did clarify afterwards - in a flippant kint of way.

They'll take 500k immediately

We are more than just StoneChecker Liquid1

https://www.imagingbiometrics.com/what-we-offer/product-services/ib-clinic/

To be fair I seem to remember the drill-pipe came from China some time last year - so long ago I've lost track

Even more ironic is not only did they forget the top-drive but the drill-pipe too. Just arriving

https://twitter.com/zenithenergyltd/status/1141635164520558592

Why uncharted? It was at 4p 12 months ago with much less progress made. The re-rate is deserved and it's consolidating well. The next phase is securing orders, income in conjunction further product development, and they are now in a far better position to achieve that. FDA for StoneChecker still to be confirmed, but as David Smith has stated previously this stuff is just routine, IB already has FDAs on other products, StoneChecker already has CE, has already secured business in the far east. Still a nascent business trying to fulfill it's potential in a hot sector, but with loads of opportunity, a maturing portfolio and plenty of room to keep progressing. GLA

The turning point for this company was when David Smith joined and I think he has the vision and the talent to take it much further - a lot of work to do but so much progress made already. This was his statement on joining last year:

David Smith, Operating CEO. Strategic overview and introductory statement:

"I have worked in the medical device business for 30 years, and as an entrepreneur in the field for the last 15 years, seeking out opportunities to improve patient healthcare and create outstanding value for shareholders. Often this work has been focused on producing a better, more efficient tool for use in the operating room. The improvements in health care delivery have been important, but relatively small, yet the businesses have been financially successful.

When I was approached by Flying Brands to become their COO, and the CEO of their operating businesses, what immediately struck me was the opportunity to be the architect in the way that healthcare is delivered. This is an opportunity for a leap in healthcare, not the creeping change I have previously successfully delivered. A healthcare revolution, not the evolution I have previously managed.

Imagine a world where expensive and invasive medical treatments are only used on patients that truly need it. Currently, resource consuming and painful biopsies are sought to confirm the presence or absence of disease in the face of ambiguous results from medical imaging. In an average hospital, hundreds of scans are taken daily, searching for disease. Imagine a software that is capable of detecting diseased patients and differentiating them from healthy patients, allowing healthcare practitioners to focus their care on the patients that need it the most. Imagine a software that improves its diagnostic capability over time, becoming more intelligent with each successful diagnosis and providing this knowledge and 'Artificial Intelligence' to those responsible for our healthcare.

Well obviously that's the risk isn't it?! If commercial success was guaranteed then you could be damn sure it wouldn't be sitting at a £2m Mcap. My argument would be that this increased market exposure makes that outcome significantly more likely and from this low level there is money to be made - others are quite entitled to take a different view and that's what makes a market.

'If he did convert them I suspect he would have more than 50% of the company which means he needs to increase the number of shares at IQAI by quite a bit before he does start to convert.'

If he did convert them - but as you well know he doesn't have to and has extended the redemption dates on earlier ones previously. They could also be transferred/sold to another party. I suspect he considers them a loan that the company will repay when capable of doing so, but time will tell of course.

Which again were CLNs subscribed to by the the chairman. Take that how you will, Trevor Brown showing great confidence or nobody else interested. From July last year to June this they've raised £1m. So burning £250k every 2-3 months is a bit misleading, particularly as the delayed process of trying to secure the FDA must have been a large Capex burden. The association with CorTech and their endorsement including StoneChecker is a significant milestone imo. Yes not actual sales yet, though Dave Smith did allude to good progress their too, but the global access they can potentially bring via their marketing agreements with very big players like GE Healthcare and others has to be seen as a huge positive. They may or may not need to raise again, as you say it depends largely on how sales go, however, there in a far better position moving forward now than 12 months ago when the SP sat at 4p. GLA

They raised £250k at the end of May via CLNs subscribed to by the chairman, see the RNS.